


WE CLAIM:

1. A compound of formula I



I,

or pharmaceutically acceptable salts and prodrugs thereof, wherein


A is selected from the group consisting of a covalent bond, CH₂, CH₂CH₂, and CH₂CH₂CH₂;

B is selected from the group consisting of CH₂ and CH₂CH₂, provided that when A is CH₂CH₂CH₂, then B is CH₂;

Y is selected from the group consisting of a covalent bond, CH₂, and CH₂CH₂;

Z is selected from the group consisting of a covalent bond, CH₂, and CH₂CH₂, provided that when Y is CH₂CH₂, then Z is a covalent bond and further provided that when Z is CH₂CH₂, then Y is a covalent bond;

R₁ is selected from the group consisting of



R₃ is selected from the group consisting of hydrogen, alkyl, and halogen;

R_4 is selected from the group consisting of hydrogen, alkoxy, alkyl, amino, halogen, and nitro;


R_5 is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aminosulfonyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, 5-tetrazolyl, $-NR_6S(O)_2R_7$, $-C(NR_6)NR_7R_8$, $-CH_2C(NR_6)NR_7R_8$, $-C(NOR_6)R_7$, $-C(NCN)R_6$, $-C(NNR_6R_7)R_8$, $-S(O)_2OR_6$, and $-S(O)_2R_6$;

R_6 , R_7 , and R_8 are independently selected from the group consisting of hydrogen and alkyl; and


R_9 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, amino, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, and phenoxy carbonyl.

2. A compound according to claim 1 wherein

R_1 is selected from the group consisting of



3. A compound according to claim 1 of formula II



II,

or pharmaceutically acceptable salts and prodrugs thereof.


4. A compound according to claim 3 wherein Y is a covalent bond and Z is CH_2 .

5. A compound according to claim 3 wherein

Y is a covalent bond;

Z is CH₂; and

R₁ is



6. A compound according to claim 5 selected from the group consisting of

(cis)-6-(3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(cis)-6-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1R,5S)-6-(3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1R,5S)-6-(5-bromo-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1R,5S)-6-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(5-ethynyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(5-vinyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

5-[(1S,5R)-3,6-diazabicyclo[3.2.0]hept-6-yl]nicotinonitrile;

(-) (cis)-6-(5-bromo-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(cis)-6-(5-bromo-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(6-bromo-5-vinyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

2-bromo-5-[(1R,5S)-3,6-diazabicyclo[3.2.0]hept-6-yl]nicotinonitrile;

(1R,5S)-6-(5-ethynyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1R,5S)-6-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(cis)-6-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;


(1R,5S)-6-(5-methoxy-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(5-methoxy-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(cis)-6-(6-bromo-5-methoxy-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1R,5S)-6-(6-chloro-5-methyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5R)-6-(6-chloro-5-methyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;
(*cis*)-6-(6-chloro-5-methyl-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;
(1R,5S)-6-(6-bromo-5-methoxy-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;
(1S,5R)-6-(6-bromo-5-methoxy-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;
(*cis*)-6-(5-azido-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;
(1R,5S)-6-(5-azido-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane; and
(1R,5S)-6-(5-azido-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane.


7. A compound according to claim 5 that is 5-[(1R,5S)-3,6-diazabicyclo[3.2.0]hept-6-yl]nicotinonitrile.
8. A compound according to claim 3 wherein Y is CH₂ and Z is a covalent bond.
9. A compound according to claim 3 wherein
 - Y is CH₂;
 - Z is a covalent bond; and
 - R₁ is
10. A compound according to claim 9 selected from the group consisting of(1R,5R)-6-(6-chloro-3-pyridinyl)-2,6-diazabicyclo[3.2.0]heptane and(1R,5R)-6-(3-pyridinyl)-2,6-diazabicyclo[3.2.0]heptane.
11. A compound according to claim 3 wherein Y is CH₂CH₂ and Z is a covalent bond.
12. A compound according to claim 3 wherein Y is CH₂ and Z is CH₂.
13. A compound according to claim 3 wherein Y is a covalent bond and Z is CH₂CH₂.

14. A compound according to claim 3 wherein

Y is a covalent bond;

Z is CH₂CH₂; and

R₁ is



15. A compound according to claim 14 selected from the group consisting of

(cis)-8-(3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(cis)-8-(6-chloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(1S,6R)-(cis)-8-(6-chloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(-) (cis)-8-(6-chloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

5-[(1R,6S)-3,8-diazabicyclo[4.2.0]oct-8-yl]nicotinonitrile;

(1S,6R)-5-[3,8-diazabicyclo[4.2.0]oct-8-yl]nicotinonitrile;

(1S,6R)-8-(5-methoxy-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(cis)-8-(5-methoxy-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(1R,6S)-8-(5-methoxy-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(cis)-8-(6-chloro-5-methyl-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(1S,6R)-8-(6-chloro-5-methyl-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(1R,6S)-8-(6-chloro-5-methyl-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(1S,6R)-8-(3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;


(1R,6S)-8-(3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(cis)-8-(5,6-dichloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;

(1S,6R)-8-(5,6-dichloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane; and

(1R,6S)-8-(5,6-dichloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane.

16. A compound according to claim 1 of formula III



III,

or pharmaceutically acceptable salts and prodrugs thereof.

17. A compound according to claim 16 wherein


Y is a covalent bond and Z is a covalent bond.

18. A compound according to claim 16 wherein

Y is a covalent bond;

Z is a covalent bond; and

R₁ is




19. A compound according to claim 18 that is (1R,5R)-2-(3-pyridinyl)-2,6-diazabicyclo[3.2.0]heptane.

20. A compound according to claim 16 wherein Y is CH₂ and Z is a covalent bond.

21. A compound according to claim 16 wherein Y is a covalent bond and Z is CH₂.


22. A compound according to claim 16 wherein
Y is a covalent bond;
Z is CH₂; and

R₁ is



23. A compound according to claim 22 selected from the group consisting of
(cis)-1-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;
(cis)-1-(6-chloro-3-pyridinyl)-5-methyoctahydropyrrolo[3,4-b]pyrrole;
(3aR,6aR)-1-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;
(3aR,6aR)-1-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;
(3aS,6aS)-1-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;
(3aS,6aS)-1-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;
5-((3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)nicotinonitrile;
(3aS,6aS)-1-(5-hydroxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole; and
5-((3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)nicotinonitrile.
24. A compound according to claim 16 wherein Y is CH₂CH₂ and Z is a covalent bond.
25. A compound according to claim 16 wherein Y is CH₂ and Z is CH₂.
26. A compound according to claim 16 wherein Y is a covalent bond and Z is CH₂CH₂.

27. A compound according to claim 1 of formula IV



IV,

or pharmaceutically acceptable salts and prodrugs thereof.

28. A compound according to claim 27 wherein


Y is a covalent bond and Z is a covalent bond.

29. A compound according to claim 27 wherein

Y is a covalent bond;

Z is a covalent bond; and

R₁ is



30. A compound according to claim 29 selected from the group consisting of

(*cis*)-3-(3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

(*cis*)-3-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane;

5-[(1*R*,5*R*)-3,6-diazabicyclo[3.2.0]hept-3-yl]nicotinonitrile; and

(1*R*,5*R*)-3-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane.


31. A compound according to claim 27 wherein Y is CH₂ and Z is a covalent bond.

32. A compound according to claim 27 wherein

Y is CH₂;

Z is a covalent bond; and

R₁ is



33. A compound according to claim 32 selected from the group consisting of

(cis)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aS,6aS)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(5,6-dichloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aS,6aS)-5-(5,6-dichloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aS,6aS)-5-(6-chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(6-chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aS,6aS)-5-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aS,6aS)-5-(5-bromo-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aS,6aS)-5-(5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(5-ethynyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(5-bromo-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

5-((3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)nicotinonitrile;

(3aR,6aR)-5-(6-bromo-5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

5-((3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-2-bromonicotinonitrile;

(3aR,6aR)-5-(5-vinyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(6-bromo-5-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;


(3aR,6aR)-5-(6-bromo-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

(3aR,6aR)-5-(5-ethyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole;

[5-((3aR,6aR)-hexahdropyrrolo[3,4-b]pyrrol-5(1H)-yl)-2-bromo-3-pyridinyl]methanol;
(3aR,6aR)-5-(6-bromo-5-vinyl-3-pyridinyl)octahdropyrrolo[3,4-b]pyrrole;
[5-((3aR,6aR)-hexahdropyrrolo[3,4-b]pyrrol-5(1H)-yl)-2-bromo-3-pyridinyl]acetonitrile; and
(3aR,6aR)-5-[6-bromo-5-(methoxymethyl)-3-pyridinyl]octahdropyrrolo[3,4-b]pyrrole.

34. A compound according to claim 27 wherein Y is a covalent bond and Z is CH₂.

35. A compound according to claim 27 wherein
Y is a covalent bond;
Z is CH₂; and
R₁ is




36. A compound according to claim 35 selected from the group consisting of


(cis)-2-(3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-methyl-5-(3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(6-chloro-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(6-chloro-3-pyridinyl)-5-methyoctahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(3-quinolinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(5-hydroxy-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(5-methoxy-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(5-ethoxy-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(5-propoxy-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(6-chloro-5-methoxy-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole;
(cis)-2-(6-chloro-5-methyl-3-pyridinyl)octahdropyrrolo[3,4-c]pyrrole; and
(cis)-2-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]octahdropyrrolo[3,4-c]pyrrole.

37. A compound according to claim 27 wherein Y is CH₂CH₂ and Z is a covalent bond.

38. A compound according to claim 27 wherein
Y is CH_2CH_2 ;
Z is a covalent bond; and
R₁ is




39. A compound according to claim 38 selected from the group consisting of
(*cis*)-6-(6-chloro-3-pyridinyl)octahydro-1H-pyrrolo[3,4-*b*]pyridine and
(*cis*)-6-(3-pyridinyl)octahydro-1H-pyrrolo[3,4-*b*]pyridine.
40. A compound according to claim 27 wherein Y is CH_2 and Z is CH_2 .
41. A compound according to claim 1 of formula V




- or pharmaceutically acceptable salts and prodrugs thereof.
42. A compound according to claim 41 wherein
Y is a covalent bond and Z is a covalent bond.
43. A compound according to claim 41 wherein Y is CH_2 and Z is a covalent bond.
44. A compound according to claim 41 wherein Y is a covalent bond and Z is CH_2 .
45. A compound according to claim 41 wherein Y is CH_2CH_2 and Z is a covalent bond.

46. A compound according to claim 41 wherein Y is CH₂ and Z is CH₂.
47. A compound according to claim 41 wherein Y is a covalent bond and Z is CH₂CH₂.
48. A compound according to claim 1 of formula VI



or pharmaceutically acceptable salts and prodrugs thereof.


49. A compound according to claim 48 wherein
Y is a covalent bond and Z is a covalent bond.
50. A compound according to claim 48 wherein Y is CH₂ and Z is a covalent bond.
51. A compound according to claim 48 wherein Y is a covalent bond and Z is CH₂.
52. A compound according to claim 48 wherein Y is CH₂CH₂ and Z is a covalent bond.
53. A compound according to claim 48 wherein Y is CH₂ and Z is CH₂.
54. A compound according to claim 48 wherein Y is a covalent bond and Z is CH₂CH₂.
55. A compound according to claim 1 of formula VII



or pharmaceutically acceptable salts and prodrugs thereof.

56. A compound according to claim 55 wherein
Y is a covalent bond and Z is a covalent bond.


57. A compound according to claim 55 wherein
Y is a covalent bond;
Z is a covalent bond; and
R₁ is



58. A compound according to claim 57 selected from the group consisting of
(*cis*)-3-(3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;
(*cis*)-3-(6-chloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane;
(1*R*,6*S*)-3-(6-chloro-3-pyridinyl)-3,8-diazabicyclo[4.2.0]octane; and
(*cis*)-5-[3,8-diazabicyclo[4.2.0]oct-3-yl]nicotinonitrile.

59. A compound according to claim 55 wherein Y is CH₂ and Z is a covalent bond.


60. A compound according to claim 55 wherein
Y is a covalent bond;
Z is a covalent bond; and
R₁ is



61. A compound according to claim 60 that is (*cis*)-6-(3-pyridinyl)octahydro-1*H*-pyrrolo[2,3-c]pyridine.

62. A compound according to claim 55 wherein Y is CH₂CH₂ and Z is a covalent bond.

63. A compound according to claim 1 of formula VIII



VIII,

or pharmaceutically acceptable salts and prodrugs thereof.


64. A compound according to claim 63 wherein

Y is a covalent bond and Z is a covalent bond.

65. A compound according to claim 63 wherein Y is CH_2 and Z is a covalent bond.

66. A compound according to claim 63 wherein Y is a covalent bond and Z is CH_2 .

67. A compound according to claim 1 of formula IX



IX,

or pharmaceutically acceptable salts and prodrugs thereof.

68. A compound according to claim 67 wherein

Y is a covalent bond and Z is a covalent bond.

69. A compound according to claim 67 wherein Y is CH_2 and Z is a covalent bond.

70. A compound according to claim 67 wherein Y is a covalent bond and Z is CH_2 .

71. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

72. A method for selectively controlling neurotransmitter release in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

73. A method of treating a disorder wherein the disorder is ameliorated by controlling neurotransmitter release in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1.

74. The method of claim 73 wherein the disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder, depression, nicotinic withdrawal syndrome, Tourette's syndrome, and schizophrenia.

75. The method of claim 73 wherein the disorder is pain.

76. A method of treating pain in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 in combination with a non-steroid anti-inflammatory agent and a pharmaceutically acceptable carrier.

77. A method of treating pain in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 in combination with an opioid and a pharmaceutically acceptable carrier.

78. A method of treating pain in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 in combination with a tricyclic antidepressant and a pharmaceutically acceptable carrier.

79. A method of treating pain in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 in combination with an anticonvulsant and a pharmaceutically acceptable carrier.